DNER and diffuse large B-cell lymphoma: Decreased BRD4 has consequently been shown to suppress a number of oncogenes such as c-MYC, BCL-6 and BCL-2 in DLBCL and other hematological malignancies, suggesting BET inhibition may be a valid therapeutic option to consider [5,6,7,8,9].